ScripFully two years into the COVID-19 pandemic, biopharmaceutical companies and academic/non-profit research organizations continue to partner on efforts to prevent and combat infections by the SARS-CoV-2
In VivoAdvanced therapies, pricing and reimbursement challenges, oncology breakthroughs and digital technologies are among the key topics for 2019 identified by biopharma industry players and watchers. More
ScripImutex Ltd .'s potential universal flu synthetic-peptides vaccine, FLU-v, has achieved the primary endpoint in a Phase IIb viral challenge study after additional analyses, updating an initial conclusi
ScripAdvanced therapies, pricing and reimbursement challenges, oncology breakthroughs and digital technologies are among the key topics for 2019 identified by biopharma industry players and watchers. Scri